Ticker brief
CANF
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
35
authors 14d
17
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-06-26 → 2026-07-02 · now +0.20 (−1 bearish … +1 bullish)
Who spoke17
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @DekmarTrades | C | -1.16 | 8 | +0.20 |
| @Greatstockpix | C | -0.61 | 4 | +0.00 |
| @BPharmCatalyst | C | · | 3 | +0.48 |
| @KevOfMomentum | C | -2.23 | 3 | +0.40 |
| @timothysykes | C | -1.78 | 2 | +0.27 |
| @OpenOutcrier | C | · | 2 | +0.47 |
| @OzmosiHealth | C | · | 2 | +0.47 |
| @DavidScottAdams | C | -0.68 | 2 | +0.25 |
| @BankTheTrade | C | -1.08 | 1 | +0.45 |
| @ABBONews | C | · | 1 | +0.40 |
| @BioStocks | C | -0.39 | 1 | +0.55 |
| @TT_stocks_ | C | +2.39 | 1 | +0.40 |
| @cfaryanoconnell | C | -0.51 | 1 | +0.10 |
| @fwpharma | B | +0.22 | 1 | +0.45 |
| @PrismMarketView | C | · | 1 | +0.50 |
| @AlertsAndNews | C | +1.52 | 1 | +0.25 |
| @BAlmohsin1 | C | -1.10 | 1 | +0.20 |
Recent signals30of 35 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-07-02 | @BAlmohsin1 | +0.20 | Arabic recap of prior session stock gains exceeding the 2% educational target. | · | tweet ↗ |
| 2026-07-01 | @DavidScottAdams | +0.25 | Momentum watchlist for tomorrow with listed tickers. | · | tweet ↗ |
| 2026-07-01 | @AlertsAndNews | +0.25 | Daily recap of alerts hitting targets, including 100%+ LHAI and SURG entry. | · | tweet ↗ |
| 2026-07-01 | @BPharmCatalyst | +0.55 | CANF Phase 2a study met primary safety endpoint and showed durable survival. | · | tweet ↗ |
| 2026-07-01 | @DavidScottAdams | +0.25 | Power hour watchlist with listed momentum tickers. | · | tweet ↗ |
| 2026-07-01 | @PrismMarketView | +0.50 | CANF Phase 2a data met primary safety endpoint and showed durable survival; stock surging 65%. | · | tweet ↗ |
| 2026-07-01 | @KevOfMomentum | +0.25 | Morning recap identifies CANF and LHAI as prior breadwinners. | · | tweet ↗ |
| 2026-07-01 | @fwpharma | +0.45 | Can-Fite posted positive mid-stage data for an oral pancreatic cancer drug. | · | tweet ↗ |
| 2026-07-01 | @OzmosiHealth | +0.70 | Phase 2a pancreatic cancer study achieves primary safety endpoint and durable survival outcomes. | · | tweet ↗ |
| 2026-07-01 | @DekmarTrades | +0.20 | Watchlist with breakout/squeeze levels for SDOT, CANF, CCXI and JEM, but no explicit entry intent. | · | tweet ↗ |
| 2026-07-01 | @DekmarTrades | +0.00 | Lists main watch tickers without trade intent or stance. | · | tweet ↗ |
| 2026-07-01 | @cfaryanoconnell | +0.10 | Lists top stocks to watch. | · | tweet ↗ |
| 2026-07-01 | @DekmarTrades | +0.00 | Lists top stocks to watch without concrete trade intent or stance. | · | tweet ↗ |
| 2026-07-01 | @KevOfMomentum | +0.65 | Look for CANF entry if it breaks supply and reclaims VWAP — States conditional entry opportunities if CANF breaks supply and reclaims VWAP. | · | tweet ↗ |
| 2026-07-01 | @DekmarTrades | +0.20 | Lists tickers with best press releases this morning as a watchlist-style signal. | · | tweet ↗ |
| 2026-07-01 | @OpenOutcrier | +0.50 | Phase 2a study achieved primary safety endpoint and durable survival outcomes. | · | tweet ↗ |
| 2026-07-01 | @Greatstockpix | +0.00 | Updated gapper watch list with tickers and chart link. | · | tweet ↗ |
| 2026-07-01 | @DekmarTrades | +0.00 | States CANF is bullish above VWAP and bearish under it, a technical level setup. | · | tweet ↗ |
| 2026-07-01 | @BPharmCatalyst | +0.55 | CANF Phase 2a Namodenoson trial met safety endpoint and showed durable survival. | · | tweet ↗ |
| 2026-07-01 | @Greatstockpix | +0.00 | Gapper watch list with tickers but no explicit stance. | · | tweet ↗ |
| 2026-07-01 | @KevOfMomentum | +0.30 | Top 3 premarket watchlist tickers without explicit entry intent in text. | · | tweet ↗ |
| 2026-07-01 | @timothysykes | +0.20 | Lists big premarket runners being watched. | · | tweet ↗ |
| 2026-07-01 | @TT_stocks_ | +0.40 | Exited CANF after entry at 3.27 and quick move to 5.00+. | · | tweet ↗ |
| 2026-07-01 | @DekmarTrades | +0.50 | Can-Fite Phase 2a pancreatic cancer study achieved primary safety endpoint and durable survival outcomes. | · | tweet ↗ |
| 2026-07-01 | @BioStocks | +0.55 | CANF Phase 2a pancreatic cancer study achieved safety endpoint and durable survival outcomes. | · | tweet ↗ |
| 2026-06-26 | @OzmosiHealth | +0.25 | Can-Fite secures Japanese patent allowance for Namodenoson's anti-obesity technology. | · | tweet ↗ |
| 2026-06-26 | @BPharmCatalyst | +0.35 | Japan Patent Office granted CANF patent for Namodenoson and other A3AR agonists. | · | tweet ↗ |
| 2026-06-26 | @OpenOutcrier | +0.45 | Can-Fite secures Japanese patent allowance for anti-obesity technology. | · | tweet ↗ |
| 2026-06-26 | @Greatstockpix | +0.00 | Updated gapper watch list names multiple tickers without entry intent. | · | tweet ↗ |
| 2026-06-26 | @ABBONews | +0.40 | Japan Patent Office allowed patent application for Namodenoson obesity use. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.